Order Article Reprints

Díaz-Tejedor A, Rodríguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-Rodríguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, Corchete LA, González-Méndez L, et al. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. International Journal of Molecular Sciences. 2024; 25(9):4718. https://doi.org/10.3390/ijms25094718

Díaz-Tejedor, Andrea, Javier Rodríguez-Ubreva, Laura Ciudad, Mauro Lorenzo-Mohamed, Marta González-Rodríguez, Bárbara Castellanos, Janet Sotolongo-Ravelo, Laura San-Segundo, Luis A. Corchete, Lorena González-Méndez, and et al. 2024. "Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands" International Journal of Molecular Sciences 25, no. 9: 4718. https://doi.org/10.3390/ijms25094718

Díaz-Tejedor, A., Rodríguez-Ubreva, J., Ciudad, L., Lorenzo-Mohamed, M., González-Rodríguez, M., Castellanos, B., Sotolongo-Ravelo, J., San-Segundo, L., Corchete, L. A., González-Méndez, L., Martín-Sánchez, M., Mateos, M.-V., Ocio, E. M., Garayoa, M., & Paíno, T. (2024). Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. International Journal of Molecular Sciences, 25(9), 4718. https://doi.org/10.3390/ijms25094718